Alembic Pharmaceuticals Posts 12% Profit Growth in Q1 FY25

~ US Generics Revenue Climbs 18% to Rs. 461 Crores for the Quarter~

Bengaluru, August 9^th 2024: Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30^th June, 2024.

Financial Highlights – For the Quarter

• Net Sales increased 5% to Rs.1562 crores.
• Net Profit up 12% to Rs.135 crores.
• EBITDA up 14% to Rs. 239 crores.

Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said “India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth.

The USFDA conducted an audit at our Formulation facility F1, without any observations, underscoring our dedication to compliance and quality. The US business grew by 18% during the quarter”

Operational Highlights – India Branded Business

• India Branded Business grew 9% to Rs. 572 crores for the quarter.
• Recorded robust growths in specialty therapies like Gynaecology, Gastrointestinal, Anti Diabetic and Ophthalmology therapies and performed relatively better than the market in acute therapies.
• Excess heat waves in Q1 FY 25 lead to unnatural market disturbances in affected geographies.
• Animal Health business grew 23% for the quarter with basket of strong brands driving outperformance.
• New launches continue to do well along with promising future launches across key segments.

International Business

• US Generics grew 18% to Rs. 461 crores for the quarter.
• 2 Launches in the US market during the quarter.
• Ex-US International Formulations grew 2% to Rs. 271 crores for the quarter.
• 206 Cumulative ANDA approvals.

API Business

• API business at Rs. 259 crores for the quarter.

The summary of Total Revenue is as under:

                                                                                               (Rs in Crores)